Difference between revisions of "Cancer drugs"
Jump to navigation
Jump to search
| (2 intermediate revisions by the same user not shown) | |||
| Line 18: | Line 18: | ||
| Herceptin | | Herceptin | ||
| 3345 Euros/month<ref name=spiegel8_8_11_124/> | | 3345 Euros/month<ref name=spiegel8_8_11_124/> | ||
| breast cancer, stomach cancer | | [[breast cancer]], stomach cancer | ||
| notes? | | notes? | ||
|- | |- | ||
| Line 25: | Line 25: | ||
| 3496 Euros/month<ref name=spiegel8_8_11_124/> | | 3496 Euros/month<ref name=spiegel8_8_11_124/> | ||
| [[lung cancer]] | | [[lung cancer]] | ||
| EGFR inhibitor - like erlotinib | | [[EGFR inhibitor]] - like erlotinib | ||
|- | |- | ||
| panitumumab | | panitumumab | ||
| Vectibix | | Vectibix | ||
| 3537 Euros/month<ref name=spiegel8_8_11_124/> | | 3537 Euros/month<ref name=spiegel8_8_11_124/> | ||
| indication | | indication ??? | ||
| notes? | | notes? | ||
|- | |- | ||
| Line 42: | Line 42: | ||
| Femara | | Femara | ||
| 4189 Euros/month<ref name=spiegel8_8_11_124/> | | 4189 Euros/month<ref name=spiegel8_8_11_124/> | ||
| indication | | indication ??? | ||
| non-steroidal aromatase inhibitor | | non-steroidal aromatase inhibitor | ||
|- | |- | ||
| Line 48: | Line 48: | ||
| Gleevec/Glivec | | Gleevec/Glivec | ||
| 4189 Euros/month<ref name=spiegel8_8_11_124/> | | 4189 Euros/month<ref name=spiegel8_8_11_124/> | ||
| ALL, CML | | ALL, [[CML]] | ||
| tyrosine kinase inhibitor | | [[tyrosine kinase inhibitor]] | ||
|- | |- | ||
| dasatinib | | dasatinib | ||
| Line 55: | Line 55: | ||
| 7513 Euros/month<ref name=spiegel8_8_11_124/> | | 7513 Euros/month<ref name=spiegel8_8_11_124/> | ||
| ALL, CML | | ALL, CML | ||
| tyrosine kinase inhibitor | | [[tyrosine kinase inhibitor]] | ||
|- | |- | ||
| nilotinib | | nilotinib | ||
| Tasigna | | Tasigna | ||
| 5685 Euros/month<ref name=spiegel8_8_11_124/> | | 5685 Euros/month<ref name=spiegel8_8_11_124/> | ||
| CML | | [[CML]] | ||
| tyrosine kinase inhibitor | | [[tyrosine kinase inhibitor]] | ||
|- | |- | ||
| lapatinib | | lapatinib | ||
| Line 72: | Line 72: | ||
==See also== | ==See also== | ||
*[[Cancer]]. | *[[Cancer]]. | ||
*[[Neoadjuvant therapy]]. | |||
==References== | ==References== | ||
Latest revision as of 15:51, 18 March 2018
This article covers cancer drugs from a pathology perspective.
Drugs in a table
| Non-proprietary name | Trade name | Cost | Indication | Notes |
|---|---|---|---|---|
| cetuximab | Erbitux | 5267 Euros/month[1] | stomach cancer, head & neck cancer | notes? |
| trastuzumab | Herceptin | 3345 Euros/month[1] | breast cancer, stomach cancer | notes? |
| gefitinib | Iressa | 3496 Euros/month[1] | lung cancer | EGFR inhibitor - like erlotinib |
| panitumumab | Vectibix | 3537 Euros/month[1] | indication ??? | notes? |
| fulvestrant | Faslodex | 719 Euros/month[1] | breast cancer | selective estrogen receptor down-regulator (SERD) |
| letrozole | Femara | 4189 Euros/month[1] | indication ??? | non-steroidal aromatase inhibitor |
| imatinib | Gleevec/Glivec | 4189 Euros/month[1] | ALL, CML | tyrosine kinase inhibitor |
| dasatinib | Sprycel | 7513 Euros/month[1] | ALL, CML | tyrosine kinase inhibitor |
| nilotinib | Tasigna | 5685 Euros/month[1] | CML | tyrosine kinase inhibitor |
| lapatinib | Tyverb | 3441 Euros/month[1] | breast cancer | tyrosine kinase inhibitor / HER2 growth receptor pathway blockade |